Athira Pharma (NASDAQ:ATHA) Now Covered by Analysts at Rodman & Renshaw

Rodman & Renshaw began coverage on shares of Athira Pharma (NASDAQ:ATHA) in a research report released on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $22.00 price target on the stock.

Separately, JMP Securities reaffirmed a market outperform rating and issued a $19.00 price objective on shares of Athira Pharma in a report on Thursday, June 20th.

Athira Pharma Price Performance

ATHA opened at $3.11 on Monday. The business has a fifty day simple moving average of $2.96 and a 200 day simple moving average of $2.81. Athira Pharma has a 1 year low of $1.33 and a 1 year high of $4.30. The company has a market capitalization of $119.20 million, a PE ratio of -1.02 and a beta of 2.90.

Athira Pharma (NASDAQ:ATHA) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.05. Equities analysts anticipate that Athira Pharma will post -2.79 earnings per share for the current fiscal year.

Insider Activity at Athira Pharma

In other Athira Pharma news, Director Kelly A. Romano bought 27,400 shares of Athira Pharma stock in a transaction on Monday, June 24th. The shares were purchased at an average price of $2.42 per share, with a total value of $66,308.00. Following the acquisition, the director now owns 80,715 shares in the company, valued at approximately $195,330.30. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Kelly A. Romano acquired 27,400 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was acquired at an average cost of $2.42 per share, for a total transaction of $66,308.00. Following the transaction, the director now directly owns 80,715 shares in the company, valued at $195,330.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kelly A. Romano bought 15,000 shares of the business’s stock in a transaction on Friday, June 21st. The stock was bought at an average price of $2.26 per share, for a total transaction of $33,900.00. Following the transaction, the director now directly owns 53,315 shares of the company’s stock, valued at $120,491.90. The disclosure for this purchase can be found here. 19.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Athira Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. American Century Companies Inc. raised its position in Athira Pharma by 9.4% in the second quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock valued at $103,000 after purchasing an additional 3,333 shares during the last quarter. Forefront Analytics LLC raised its holdings in Athira Pharma by 43.0% in the 4th quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock valued at $72,000 after buying an additional 8,955 shares during the last quarter. Renaissance Technologies LLC boosted its position in Athira Pharma by 3.5% during the 2nd quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock worth $719,000 after buying an additional 9,164 shares during the period. Rothschild Investment LLC bought a new stake in Athira Pharma during the 2nd quarter worth approximately $34,000. Finally, Private Advisor Group LLC acquired a new position in Athira Pharma in the 4th quarter valued at approximately $32,000. Institutional investors own 57.12% of the company’s stock.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.